Tuesday, 16 December 2025 Reading time : 4 minutes

The research department of the Zürcher Kantonalbank has identified ten Swiss equities that it believes have particularly good prospects for the year 2026. The Tracker Certificate on «ZKB Jahresfavoriten 2026» allows investors to invest in this selection.

Five stock market heavyweights
One of the favourites among large caps is ABB, a leading global provider of electrification and automation solutions. According to ZKB analysts, the group is benefiting from the structural trend towards the electrification of industrial processes, as well as the expansion and renewal of electricity grids. Building materials manufacturer Amrize is also included in the selection. The spin-off of Holcim's North American business is expected to accelerate margin and cash flow growth thanks to rising sales momentum. ZKB Research is optimistic about Partners Group, as the company could benefit from a revival in the private equity transaction market.

The analysts see potential for a turnaround at the pharmaceutical giant Roche, based on positive research results for the drugs Giredestrant (breast cancer) and Fenebrutinib (multiple sclerosis). Zurich Insurance is expected to perform well thanks to solid business growth, a high dividend yield and potential for share price growth.

Five small and mid caps
Among small and mid caps, Accelleron is one of the favourite stocks. The global market leader for turbochargers impresses with its business model, characterised by high barriers to entry and stability. ZKB analysts expect the semiconductor equipment supplier Comet to experience significantly accelerated profit growth in 2026. Industrial supplier Dätwyler is likely to embark on a multi-year growth phase, recording considerable margin increases in the coming years. Growth prospects are also promising for the medical technology company Medacta, which is likely to benefit from its product innovations and customer proximity. Finally, Siegfried is also among the favourite stocks. The pharmaceutical supplier is a global leader in the small molecule market, with applications in oncology and GLP-1 therapies, among others.

During the initial fixing period, the ten stocks selected are added to the basket with an equal weighting of 10% each. In terms of market capitalisation, small and medi-um-sized companies therefore have a relatively higher weighting in the basket.

Investing in the «ZKB Favourite Stocks 2026»

Tracker Certificate: Full participation
The Tracker Certificate is suitable for investors who expect a positive performance of the basket and want to participate fully in this performance. 

Issue price of CHF 100.00
1 year maturity
Valor: 134 140 315
Termsheet
About the product

Outperformance Certificate: Over-proportional participation
The Outperformance Certificate is suitable for investors who expect the basket to perform positively but do not expect the cap to be exceeded. In this case, they participate disproportionately in the price gains.

145% Upside Participation
110% Cap Level (maximum return 14.50%)
Issue price of CHF 100.00
1 year maturity
Valor: 134 140 317
Termsheet
About the product

In Subscription until January 16, 2026, 12:00 CET.

Indicative terms

 

Disclaimer
This communication is for marketing purposes. It is neither an offer nor an invitation to submit an offer, to purchase or to subscribe to securities and does not constitute investment advice. You should consult your advisors before making an investment decision. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, financial condition, development or performance of the issuer to be materially different from any future results, financial condition, development or performance expressed or implied by such statements. The present document has not been drawn up by the research department as defined in the rules of the “Directives on the Independence of Financial Research” published by the Swiss Bankers Association, hence these rules do not apply to this document. If securities are mentioned in the communication, the base prospectus, the final terms and any key information document may be obtained free of charge from Zürcher Kantonalbank, Bahnhofstrasse 9, 8001 Zurich, VRIS, and from www.zkb.ch/finanzinformationen.
© 2025 Zürcher Kantonalbank. All rights reserved.